GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SNK-396 overview
SNK-396 is under development for the treatment of elevated low-density lipoprotein cholesterol. It is administered through subcutaneous route.
Synerk overview
Synerk is engaged in providing biotechnology services. It develops RNA targeted medicines for breast cancer, lung cancer, mouth cancer and stomach cancer. This company is headquartered in Concord, Massachusetts, the US.
For a complete picture of SNK-396’s drug-specific PTSR and LoA scores, buy the report here.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Source link
#SNK396 #Synerk #Lipid #Disorders #Likelihood #Approval
